NCT05922930View on ClinicalTrials.gov

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

October 15, 2027

Study Completion Date

January 15, 2028

Conditions
Pancreatic CancerOvarian CancerAdenocarcinoma
Interventions
DRUG

TROP2-CAR-NK

Given by IP (intraperitoneal)

DRUG

Cyclophosphamide

Given by IV (vein)

DRUG

Fludarabine

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER